General Information of Drug (ID: DM71BFM)

Drug Name
DNA-Ad Drug Info
Synonyms DNA-prime/adenovirus (Ad5)-boost CSP-and AMA1-encoding malaria vaccine (Biojector2000, intramuscular), US NavalMedical Research Center (NMRC)/Bioject/Vical/GenVec
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM71BFM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AdCh63 AMA1 DMEGPSW Malaria 1F40-1F45 Phase 1/2 [3]
PfAMA-1 DMLDZX1 Malaria 1F40-1F45 Phase 1 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Apical membrane protein (Malaria AMA-1) TTQZW34 AMA1_PLAFF Not Available [2]

References

1 ClinicalTrials.gov (NCT00870987) Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria. U.S. National Institutes of Health.
2 Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014 Sep 11;9(9):e106241.
3 ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health.
4 Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite devel... J Cell Sci. 2003 Sep 15;116(Pt 18):3825-34.